Natus Becomes Private to Overcome Supply Chain Woes

Archimed, a European investment firm, has completed its $1.2 billion acquisition of Natus Medical. The move takes the Middleton, WI-based company private.

Natus develops solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems.

In conjunction with the closing of the transaction, Natus Chief Commercial Officer Austin Noll III was promoted to President of Natus. The promotion follows. Noll's exemplary career of over 10 years of leadership at Natus.

“ArchiMed's mix of operational, medical, scientific and financial expertise will help us continue our mission to serve our customers as we internationalize and grow our business,” said Thomas J. Sullivan, CEO of Natus. “Our Natus Teammates are excited to advance the standard of care and improve outcomes and quality of life for patients affected by disorders of the brain, neural pathways, and eight sensory nervous systems as a part of ArchiMed.”

The deal comes on the heels of Natus noting it was facing extraordinary supply chain issues. Natus highlighted the issues during a November earnings call. The company noted got slammed with $3.4 million of supply chain costs associated with buying semiconductors in the first quarter.